Hyaluronidase Delivering Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: Important Considerations.. Important Considerations
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Hyaluronidase Delivering Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: Important Considerations.. Important Considerations
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Presented at: Specialty Pharmaceutical Summit 2025 SPS Puerto Rico
Summit Directors:
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE | Baptist Health South Florida
Bhavesh Shah, RPh, BCOP | Boston Medical Center
Panel Discussion: Hyaluronidase Delivering New Subcutaneous Dosage Forms Throughout Various Therapeutic Areas: Important Considerations
Moderator: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE | Baptist Health South Florida
Panel: Héctor J. Hernández, PharmD, RPh, MPH, CSP | Special Care Pharmacy Services, Belmarie Palen, PharmD, CSP | Axium Healthcare Puerto Rico, Gladiany Ramos-Marrero, PharmD, RPh, CSP | MCS Puerto Rico, Nicole Quiles Alves, PharmD, RPh, MPH | Axium Healthcare de Puerto Rico, Specialty Pharmacy
The panel discussion highlighted the potential of subcutaneous (sub Q) formulations to enhance patient care and efficiency, while addressing challenges such as accesslimitations, step therapy requirements, and reimbursement issues in Puerto Rico. Emphasis was placed on the need for collaboration among providers, payers, and specialty pharmacies to optimize outcomes and manage costs.